GSA Capital Partners LLP Makes New $406,000 Investment in Immunocore Holdings plc (NASDAQ:IMCR)

GSA Capital Partners LLP acquired a new position in shares of Immunocore Holdings plc (NASDAQ:IMCR) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 13,039 shares of the company’s stock, valued at approximately $406,000.

Other large investors have also recently bought and sold shares of the company. Janus Henderson Group PLC increased its position in shares of Immunocore by 45.8% in the 1st quarter. Janus Henderson Group PLC now owns 257,080 shares of the company’s stock valued at $16,711,000 after buying an additional 80,748 shares in the last quarter. Tidal Investments LLC bought a new position in Immunocore in the first quarter valued at approximately $423,000. DNB Asset Management AS increased its stake in Immunocore by 35.0% in the second quarter. DNB Asset Management AS now owns 7,211 shares of the company’s stock valued at $244,000 after acquiring an additional 1,868 shares during the last quarter. SG Americas Securities LLC increased its stake in Immunocore by 1,867.3% in the second quarter. SG Americas Securities LLC now owns 160,358 shares of the company’s stock valued at $5,435,000 after acquiring an additional 152,207 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. boosted its position in Immunocore by 6.5% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 22,622 shares of the company’s stock valued at $767,000 after buying an additional 1,390 shares in the last quarter. Institutional investors and hedge funds own 84.50% of the company’s stock.

Analysts Set New Price Targets

IMCR has been the topic of a number of research analyst reports. Guggenheim lowered shares of Immunocore from a “buy” rating to a “neutral” rating in a research report on Monday, October 7th. Mizuho lowered shares of Immunocore from an “outperform” rating to a “neutral” rating and cut their price target for the stock from $72.00 to $38.00 in a report on Monday, November 11th. Oppenheimer reiterated an “outperform” rating and set a $89.00 price target (up previously from $87.00) on shares of Immunocore in a report on Friday, August 9th. HC Wainwright reiterated a “buy” rating and set a $100.00 price target on shares of Immunocore in a report on Thursday, October 24th. Finally, Barclays cut their price target on shares of Immunocore from $92.00 to $66.00 and set an “overweight” rating on the stock in a report on Friday, August 9th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $69.18.

Immunocore Stock Performance

Immunocore stock opened at $32.12 on Friday. The firm’s 50 day simple moving average is $32.32 and its 200 day simple moving average is $37.90. The company has a current ratio of 3.78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03. The firm has a market capitalization of $1.61 billion, a PE ratio of -33.81 and a beta of 0.72. Immunocore Holdings plc has a 1-year low of $29.72 and a 1-year high of $76.98.

Immunocore (NASDAQ:IMCR) last released its earnings results on Wednesday, November 6th. The company reported $0.17 EPS for the quarter, beating the consensus estimate of ($0.33) by $0.50. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The company had revenue of $80.25 million for the quarter, compared to analyst estimates of $78.94 million. During the same quarter last year, the firm earned ($0.59) EPS. The firm’s quarterly revenue was up 23.7% compared to the same quarter last year. As a group, analysts expect that Immunocore Holdings plc will post -0.94 earnings per share for the current fiscal year.

Immunocore Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.